of innovative treatments ROG RAM
6
2 AND 3 DECEMBER 2021 VIRTUAL MEETING tolerance of innovative treatments 11 TH EDITION CANCER TOXICITY MANAGEMENT meeting TAO
Transcript of of innovative treatments ROG RAM
PROGRAM
2 AND 3 DECEMBER 2021VIRTUAL MEETING
tolerance of innovative treatments
11TH EDITION CANCERTOXICITYMANAGEMENTmeeting
TAO
pegfilgrastim 6 mg/0,6 ml
pegfilgrastim 6 mg/0,6 ml
Le tempsde leurcôtéNe laissez pas la neutropéniefébrile compromettre le programmede chimiothérapie de votre patient
Fulphila® est indiqué dans la réduction de la durée des neutropénies et de l’incidence des neutropénies fébriles chez les patients adultes traités par une chimiothérapie cytotoxique pour une pathologie maligne (à l’exception des leucémies myéloïdes chroniques et des syndromes myélodysplasiques).
L’utilisation des G-CSF en prophylaxie primaire est recommandée chez les patients soumis à un protocole comportant un risque de neutropénie fébrile supérieur à 20%, voire compris entre 10 et 20% chez certains patients pour lesquels les facteurs de risque individuels le justifient (âge > 65 ans, stade avancé de la maladie, survenue antérieure d’un ou plusieurs épisodes de neutropénies fébriles, absence d’antibiothérapie ou de G-CSF, statut nutritionnel altéré, cytopénie liée à un envahissement tumoral médullaire, traitements antérieurs extensifs).
Ce médicament fait l’objet d’une surveillance supplémentaire qui permettra l’identification rapide de nouvelles informations relatives à la sécurité.
Liste I. Médicament soumis à prescription initiale hospitalière trimestrielle.Le traitement par pegfilgrastim doit être instauré et supervisé par un spécialiste en oncologie et/ou en hématologie.
Remb. Séc. Soc. à 100% - Collect.
Mylan Medical SAS est une société du groupe Viatris
Cette spécialité est un biosimilaire de Neulasta® 6 mg.
PE
G-2
019-
0156
V2
- M
odifs
Fév
rier
2021
-Vis
a n°
20/0
1/60
4579
29/P
M/0
08
Pour une information complète, consultez le Résumé des Caractéristiques du Produit sur labase de données publique du médicament en flashant ce QR code ou directement sur le site
Internet http://base-donnees-publique.medicaments.gouv.fr
022021_3997_Viatris Fulphila Press Ad -France_SCA_A4.indd 1022021_3997_Viatris Fulphila Press Ad -France_SCA_A4.indd 1 30-03-2021 03:13:33 PM30-03-2021 03:13:33 PM
Thursday, December 2 – morning
PROGRAM
All times in this program are Central European Time (UTC+1)
9:45-10:00 AM Meeting opening Bridging supportive care and anti-cancer therapy Jean-Charles Soria (Washington D.C., USA)
10:00-10:30 AM PLENARY SESSIONDAILY DRUGS, MICROBIOTA & CANCER DRUGS: PARTNERS OR ENEMY - DANGEROUS LIAISONS?Joël Epstein (Duarte, USA)
10:00-10:15 AM Daily drugs; Antibiotics, IPP, Statins, steroids, etc. Denis Moro-Sibilot (Grenoble)
10:15-10:30 AM The gut microbiota in the modulation of anticancer drugs efficacy and toxicity : last data Lisa De Rosa (Villejuif)
10:30-11:15 AM PLENARY SESSIONCOVID 19 : THE STORM OF CANCER CAREMario Dicato (Luxembourg)
10:30-10:45 AM The impact of pandemic on Ethics and Cancer CareMatti Aapro (Switzerland)
10:45-11:00 AM The impact on supportive management Andrew Davies (UK)
11:00-11:15 AM Discussion
11:15-11:30 AM Break
11:30-12:15 AM PLENARY SESSIONNEW DRUGS & SAFETY / TUMOR LOCALIZATIONPere Gascon (Spain)
11:30-11:45 AM Gynecology Isabelle Ray-Coquard (Lyon)
11:45-12:00 AM Haemato-Oncology: Supportive care and Car T-cell therapy Stéphane Chèze (Caen)
12:00-12:15 AM Urology Yann Vano (Paris)
12:15-1:00 PM PLENARY SESSIONSUPPORTIVE AND SURVIVORSHIP CARE NEEDS AFTER CANCER TREATMENT – With the institutional support of PfizerRajesh Lalla (Connecticut)
12:15-12:30 AM Definition and guidelines Maryam Lustberg (USA)
12:30-12:45 AM Canto: A new model for research Ines Vaz Luis (Villejuif)
12:45-01:00 PM Patient’s experience and unmet needs Patient
1:00-2:00 PM Lunch
Thursday, December 2 – afternoon
PROGRAM
2:00-3:00 PM PLENARY SESSIONDIGITAL HEALTH (UPDATE) AND CANCER CONTINUUMWith the institutional support of ViatrisOlivier Mir (Villejuif)
2:00-2:15 PM Digital health for symptom monitoring Ethan Basch (USA)
2:15-2:30 PM Running to daily practice Fabrice Denis (Le Mans)
2:30-2:45 PM A review of digital programs Paolo Bossi (Brescia)
2:45-3:00 PM From hospital to home care and back Mario Di Palma (Paris)
3:00-3:30 PM Break
3:30-4:00 PM SYMPOSIUM IMMUNOTHERAPY RELATED TOXICITIES IN THE ADJUVANT SETTING: FROM THEORY TO PRACTICE?Ariane Laparra-Ramakichenin (Le Kremlin-Bicêtre), Raffaele Ratta (Suresnes)
4:00-5:30 PM CONTROVERSIES AND DIFFERENT APPROACHES Fausto Roila (Italy), Richard Gralla (USA)
4:00-4:30 PM Is cancer a matter of bad luck? Mario Dicato (Luxembourg)
4:30-5:00 PM Different approaches:CINV, best association from acute to breakthrough Richard Gralla (USA)
5:00-5:30 PM Controversies:Febrile Neutropenia, MASCC tool evidence vs ASCO Jean Klastersky (Brussels), B. L. Rapoport (South Africa)
5:30-6:15 PM YOUNG PHYSICIAN AWARD JEAN KLASTERSKYPresentation of the 3 first clinical cases (3 x 15 min)Moderators: Jean Klastersky (Brussels), Paolo Bossi (Brescia), Richard Berman (UK), Richard Gralla (USA), Ivan Krakowski (Bordeaux).
PROGRAM
8:45-9:30 AM YOUNG PHYSICIAN AWARD - JEAN KLASTERSKYPresentation of the 3 last clinical cases (3 x 15 min)Moderators: Jean Klastersky (Brussels), Paolo Bossi (Brescia), Richard Berman (UK), Richard Gralla (USA), Ivan Krakowski (Bordeaux).
9:30-10:30 AM PLENARY SESSIONOPTIMIZE CANCER CARE AND INNOVATIVE TREATMENTS IN ONCOLOGY Jeffrey Crawford (USA)
9:30-9:45 AM New drugs expected in the next future (CAR T, bispecific antibodies…) Christophe Massard (Rennes)
9:45-10:00 AM New coming toxicities Jean-Marie Michot (Villejuif)
10:00-10:15 AM Managing the safetyOlivier Lambotte (Le Kremlin-Bicêtre)
10:15-10:30 AM How to deal with frailty Gilles Freyer (Lyon)
10:30-11:00 AM PLENARY SESSIONLONG TERM SAFETY AFTER IMMUNE-ONCOLOGY With the institutional support of MSDPaolo Bossi (Brescia)
10:30-10:40 AM Long term toxicity: are they similar with the acute? Edith Borcoman (Paris)
10:40-10:50 AM How to prevent / manage long term toxicity? Delphine Loirat (Paris)
10:50-11:00 AM Monitoring interest Paolo Bossi (Brescia)
11:00-11:30 AM Break
11:30-12:00 AM SYMPOSIUM FEVER AND CANCER: THE ISSUE Gilles Freyer (Lyon), Didier Mayeur (Dijon)
12:00-12:30 PM PLENARY SESSION VACCINATION AND SUPPORTIVE CARE IN CANCER DURING PANDEMICS AND BEYONDFausto Roila (Italy)
12:00-12:15 PM Covid vaccination: The MDAnderson experience Ishwaria Mohan Subbiah (USA)
12:15-12:30 PM Covid vaccine, what else? Benjamin Wyplosz (Le Kremlin-Bicêtre)
12:30-1:30 PM Lunch
Friday, December 3 – morning
Friday, December 3 – afternoon
1:30-2:30 PM PLENARY SESSIONNEW DRUGS & SAFETY / TUMOR LOCALIZATION Richard Gralla (USA)
1:30-1:45 PM Breast Joseph Gligorov (Paris)
1:45-2:00 PM GI Jérôme Desrame (Lyon)
2:00-2:15 PM Lung Nicolas Girard (Paris)
2:15-2:30 PM Session Q/R
2:30-3:00 PM THE NEW AFSOS STANDARDSWith the institutional support of LEO PharmaIsmail Elalamy (Paris)
3:00-3:30 PM Break
3:30-3:45 PM YOUNG PHYSICIAN AWARD JEAN KLASTERSKYAward ceremonyModerators: Jean Klastersky (Brussels), Paolo Bossi (Brescia), Richard Berman (UK), Richard Gralla (USA), Ivan Krakowski (Bordeaux).
3:45-4:45 PM PLENARY SESSIONLET’S TALK ABOUT SEXRichard Berman (UK)
3:45-4:00 PM Why to discuss and when - the main sexual complaints Marion Aupomerol (Villejuif)
4:00-4:15 PM How to discuss Richard Berman (UK)
4:15-4:30 PM Let’s talk about sexual minorities: the ASCO survey Charles Stewart Kamen (USA), Mandi Pratt-Chapman (USA), Shail Maingi (USA)
4:30-4:45 PM Session Q/R
4:45-5:00 PM CONCLUSION Florian Scotté (Villejuif)
With the support of our partners
Registration and information:
[email protected] www.tao-ctmmeeting.com
PROGRAM
Partner of the Young Physician Award Jean Klastersky:
